Plain-English translation of NCT06680089 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new diagnostic scan called immunoPET/CT imaging in patients with kidney cancer or suspected kidney cancer. The scan uses a special tracer (a harmless radioactive substance) that targets cancer cells to create detailed pictures of your body. Researchers want to see if this new scan is better at finding kidney cancer and spotting spread compared to standard imaging methods like CT, MRI, or conventional PET scans.
Doctors need better ways to detect kidney cancer early and find out if it has spread to other parts of the body, because current imaging methods don't always catch all the cancer. This medication is designed to highlight kidney cancer cells specifically, which may help doctors diagnose and stage the disease more accurately and make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the tracer substance and then return for a specialized scan about one hour later. The scan itself is painless and non-invasive—you simply lie still while the scanner takes pictures of your whole body. Researchers will compare the images from this new scan with your previous imaging tests (CT, MRI, or other scans) to see how well it detects kidney cancer.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
RenJi Hospital
Enrollment target
~300 participants
Started
November 2024
Primary completion
November 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weijun Wei, Ph.D. & M.D.
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.